Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Illumina Inc (NASDAQ:ILMN), a genetic testing company, has been ordered by EU antitrust regulators to sell Grail after closing its takeover of the cancer test maker before securing their approval. In a statement, the European Commission said it has adopted, under the EU Merger Regulation, “restorative measures requiring Illumina to unwind its completed acquisition of Grail.

Illumina ordered by European Commission to sell cancer test maker Grail

U.S. genetic testing company Illumina has been ordered by EU antitrust regulators to sell cancer test maker Grail after it completed the deal before securing their approval.

Illumina ordered by EU antitrust regulators to sell Grail

Illumina Inc said on Wednesday it will divest Grail if the company loses the final appeals in U.S. or European courts.

Illumina to divest Grail if it loses final court appeals

SAN DIEGO , Oct. 11, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) posted a stewardship-focused presentation for investors on the Events & Presentations section of its investor relations website, investor.illumina.com, on Wednesday, October 11, 2023. Members of Illumina's Board of Directors and senior management may use this presentation during meetings with investors.

Illumina Posted a Stewardship-Focused Presentation for Investors

U.S. genetic testing company Illumina will on Thursday get an order from EU antitrust regulators to sell cancer test maker Grail , a year after the $7.1 billion deal was blocked, a person with direct knowledge of the matter said on Tuesday.

Illumina to get EU order on Thursday to divest Grail, source says

Ligand Pharmaceuticals

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Ligand Pharmaceuticals (LGND) or Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?

LGND vs. ILMN: Which Stock Should Value Investors Buy Now?

An order from EU competition regulators for Illumina to sell cancer detection test maker Grail could come as early as next week, the Financial Times reported on Monday, citing people with knowledge of the matter.

EU regulatory order for Illumina to sell Grail could come next week - FT

Illumina ( ILMN ), the maker of million-dollar genome sequencing machines that revolutionized the fields of genetics and biotechnology, has fallen hard in the past year. And some analysts believe the pain is not over.

Bear of the Day: Illumina (ILMN)

Johnson & Johnson

Merck

Moderna

UnitedHealth Group

Zimmer Biomet Hlds

With the current sector-wide downturn, it's not surprising that several large healthcare stocks are currently undervalued, relative to their intrinsic value, based on their fundamentals, cash flows, and future earnings potential.

3 Undervalued Healthcare Stocks to Watch as Sector Struggles

LOS ANGELES, CA / ACCESSWIRE / October 6, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Illumina, Inc. ("Illumina" or "the Company") (NASDAQ:ILMN) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Stratasys board breached its fiduciary duties to shareholders.

GRAIL SHAREHOLDER INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm

SAN DIEGO , Oct. 5, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the third quarter 2023 following the close of market on Thursday, November 9, 2023.  On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Jacob Thaysen, Chief Executive Officer, and Joydeep Goswami, Chief Financial Officer and Chief Strategy and Corporate Development Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Illumina to Announce Third Quarter 2023 Financial Results on Thursday, November 9, 2023

LOS ANGELES, CA / ACCESSWIRE / September 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Illumina, Inc. ("Illumina" or "the Company") (NASDAQ:ILMN) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Stratasys board breached its fiduciary duties to shareholders.

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm

FirstEnergy

As the market continues to juggle high interest rates and inflation and the third quarter prepares to come to a close later this week, a couple stocks in Carl Icahn (Trades, Portfolio)'s equity portfolio have retreated near their 52-week lows.

2 of Carl Icahn's Holdings Approach 52-Week Lows

SAN FRANCISCO--(BUSINESS WIRE)-- #biotech--Illumina Ventures today announced that Mara Aspinall, MBA, has joined the Company's investment team as a Partner.

Illumina Ventures Announces New Partner, Mara Aspinall, Has Joined Its Investment Team

Illumina, Inc. (NASDAQ:ILMN ) Morgan Stanley 21st Annual Global Healthcare Conference September 11, 2023 12:55 PM ET Company Participants Joydeep Goswami - Chief Financial Officer, Chief Strategy and Corporate Development Officer Salli Schwartz - Vice President of Investor Relations Conference Call Participants Tejas Savant - Morgan Stanley Tejas Savant All Right. Hey, everyone.

Illumina, Inc. (ILMN) Morgan Stanley 21st Annual Global Healthcare Conference - (Transcript)

Illumina has had a bad few years due to its troubles with the Grail purchase. It now has new management, and its fines from regulators in the E.U.

Is the Worst Over for Illumina Stock?

Gilead Sciences

abrdn Healthcare Investors 

iShares Nasdaq Biotechnology ETF

IQVIA Hlds

Direxion Daily S&P Biotech Bull 3X Shares

Lonza Group AG

Navistar

Omega Healthcare Investors

Pfizer

Royalty Pharma

abrdn World Healthcare Fund 

Wuxi Biologics Cayman Inc

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

The recent IRA list of 10 drug publications is not expected to have a significant impact on big pharma stocks in the near term. The legal challenges by big pharma companies against the IRA may derail the implementation of the drug pricing reforms. Investors can consider diversified biotech indexes or healthcare-focused ETFs for exposure to the biopharma sector.

Biopharma Bounce-Back: From Policy Pains To Profitable Plains

Activist investor Icahn's blessing is a relief for the company as it tries to rebound from a bitter proxy fight with the billionaire investor.

Carl Icahn says new Illumina CEO has his 'full support' months after proxy fight

Illumina (ILMN) said Tuesday it has chosen Agilent Technologies (A) executive Jacob Thaysen as its new chief executive officer (CEO) as the gene sequencing firm works to recover from a proxy fight with activist investor Carl Icahn and a tumbling share price.

Illumina Picks New CEO, but Shares Continue To Slide

Illumina Inc (NASDAQ:ILMN) has a new CEO following its public proxy battle with activist investor Carl Ichan over its troubled acquisition of Grail Inc. The biotech firm named former Agilent executive Jacob Thaysen as its new boss on Tuesday morning.

Illumina gets new CEO following proxy battle with Carl Ichan

Exelixis

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?

EXEL vs. ILMN: Which Stock Is the Better Value Option?

The announcement comes after a proxy fight with activist investor Carl Icahn, which ended with Illumina's former CEO Francis deSouza voluntarily stepping down.

Illumina names new CEO months after Icahn proxy fight over Grail deal

Jacob Thaysen was named to the role after Francis deSouza resigned from the gene-sequencing maker in June amid a fight with regulators.

Illumina Names New Chief Executive

Illumina Inc. ILMN, +1.96% on Tuesday announced that its board has appointed Agilent Technologies Inc. A, +0.69% senior vice president Jacob Thaysen as its new CEO, effective Sept. 25. The DNA sequencing company faced leadership turmoil after its proxy fight earlier this year with activist investor Carl Icahn, and CEO Francis deSouza stepped down in June.

Illumina names Agilent executive as new CEO

SAN DIEGO , Sept. 5, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its Board of Directors has appointed Jacob Thaysen, Ph.D.

News for Illumina Stock (ILMN)